Yahoo
NasdaqGM - Nasdaq Real Time Price USD

BrainsWay Ltd. (BWAY)

14.28 +0.01 (+0.07%)
At close: September 2 at 4:00:01 PM EDT
14.28 0.00 (0.00%)
After hours: September 2 at 7:30:04 PM EDT
Trade BWAY on Coinbase
Chart Range Bar
Loading chart for BWAY
Chart does not reflect overnight price.
  • Previous Close 14.27
  • Open 14.28
  • Bid 10.99 x 200
  • Ask 19.71 x 200
  • Day's Range 14.08 - 14.78
  • 52 Week Range 7.14 - 17.40
  • Volume 86,465
  • Avg. Volume 116,151
  • Market Cap (intraday) 574.17M
  • Beta (5Y Monthly) 0.10
  • PE Ratio (TTM) 62.09
  • EPS (TTM) 0.23
  • Earnings Date Nov 10, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 19.27

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

www.brainsway.com

129

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 9/2/2026, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .

YTD Return

BWAY
50.47%
TA-125 (^TA125.TA)
13.24%

1-Year Return

BWAY
83.55%
TA-125 (^TA125.TA)
35.67%

3-Year Return

BWAY
711.36%
TA-125 (^TA125.TA)
0.00%

5-Year Return

BWAY
258.34%
TA-125 (^TA125.TA)
126.90%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 15.53M
Earnings 2.29M
Profit Margin 14.74%

Q3

FY25

Q4

FY25

Q1

FY26

0
5M
10M
15M
12.0%
14.0%
16.0%
18.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

18.80
19.27 Average
14.28 Current
20.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/31/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 17 -> 19

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    582.91M

  • Enterprise Value

    526.87M

  • Trailing P/E

    62.04

  • Forward P/E

    19.01

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.23

  • Price/Book (mrq)

    7.25

  • Enterprise Value/Revenue

    8.68

  • Enterprise Value/EBITDA

    44.28

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.56%

  • Return on Assets (ttm)

    4.05%

  • Return on Equity (ttm)

    12.82%

  • Revenue (ttm)

    60.7M

  • Net Income Avi to Common (ttm)

    9.44M

  • Diluted EPS (ttm)

    0.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    62.11M

  • Total Debt/Equity (mrq)

    9.01%

  • Levered Free Cash Flow (ttm)

    -6.16M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

14.28 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: